SCHEMBL25192577

SCHEMBL25192577

CN(c1ccc(Br)cn1)C1CCC(C(=O)O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.42
JAK1 P23458 1/20 0.42
GBA1 P04062 1/20 0.40
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
PTGDR2 Q9Y5Y4 3/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
CACNA1H O95180 1/20 0.35
USP30 Q70CQ3 1/20 0.34
ABL1 P00519 1/20 0.34
PPARG P37231 1/20 0.34
ATM Q13315 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NCOR2 Q9Y618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192574 1.00 JAK2 (0.42) JAK2JAK1GBA1ALDH1A1KDM4E
SCHEMBL17316407 0.87 GBA1 (0.50) JAK2JAK1GBA1ALDH1A1SMN1; SMN2
SCHEMBL27022988 0.85 JAK2 (0.42) JAK2JAK1GBA1ALDH1A1KDM4E
SCHEMBL30441783 0.85 JAK2 (0.42) JAK2JAK1GBA1ALDH1A1KDM4E
SCHEMBL5025729 0.81 JAK2 (0.37) JAK2JAK1ALDH1A1KDM4ENPC1
SCHEMBL5025727 0.81 JAK2 (0.37) JAK2JAK1ALDH1A1KDM4ENPC1
SCHEMBL31217324 0.81 JAK1 (0.47) JAK2JAK1GBA1ALDH1A1SMN1; SMN2
SCHEMBL31217199 0.79 SMN1; SMN2 (0.49) JAK2JAK1GBA1ALDH1A1SMN1; SMN2
SCHEMBL25188963 0.78 POLB (0.40) KMT2ANPC1MAPTRAB9APOLB
SCHEMBL25265331 0.78 POLB (0.40) KMT2ANPC1MAPTRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. 2024-01-18 US disclosed
WO-2023086399-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018162-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 JAK2 1297/4885JAK1 1428/4885GBA1 2842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.